Further drug-target analyses indicated that highergenetically predicted circulating PCSK9 and lipoprotein(a) wereassociated with an increased AAA risk, and a pre-clinical mouse model validatedthe important role of PCSK9 in AAA development [46]. This evidence concerns the gene PCSK9 and triple-A syndrome.